
ProKidney (PROK) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
230.0K
Operating Income
-41.4M
-17,994.78%
Net Income
-38.0M
-16,500.87%
EPS (Diluted)
$-0.13
Balance Sheet Metrics
Total Assets
406.1M
Total Liabilities
36.1M
Shareholders Equity
370.0M
Debt to Equity
0.10
Cash Flow Metrics
Operating Cash Flow
-35.1M
Free Cash Flow
-30.7M
Revenue & Profitability Trend
ProKidney Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 76.0K | 0 | 0 | 0 | 0 |
Cost of Goods Sold | - | - | - | - | - |
Gross Profit | - | - | - | - | - |
Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 127.7M | 106.7M | 82.1M | 46.3M | 21.0M |
Selling, General & Administrative | 56.1M | 44.8M | 70.9M | 8.9M | 6.0M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 183.8M | 151.5M | 153.0M | 55.1M | 27.0M |
Operating Income | -183.7M | -151.5M | -153.0M | -55.1M | -27.0M |
Operating Margin % | -241,678.9% | 0.0% | 0.0% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | 19.8M | 22.1M | 6.0M | 2.0K | 43.0K |
Interest Expense | 9.0K | 12.0K | 215.0K | 0 | 0 |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -163.9M | -129.5M | -147.2M | -55.1M | -27.0M |
Income Tax | -598.0K | 6.0M | 896.0K | 38.0K | -232.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -163.3M | -135.4M | -148.1M | -55.1M | -26.7M |
Net Margin % | -214,914.5% | 0.0% | 0.0% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | -158.5M | -125.6M | -144.0M | -53.1M | -26.0M |
EPS (Basic) | $-0.62 | $-0.57 | $-0.23 | $-0.30 | $-0.14 |
EPS (Diluted) | $-0.62 | $-0.57 | $-0.23 | $-0.30 | $-0.14 |
Basic Shares Outstanding | 97916193 | 61714225 | 61540231 | 186500000 | 186500000 |
Diluted Shares Outstanding | 97916193 | 61714225 | 61540231 | 186500000 | 186500000 |
Income Statement Trend
ProKidney Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 99.1M | 60.6M | 490.3M | 20.6M | 4.6M |
Short-term Investments | 259.2M | 302.3M | 0 | - | - |
Accounts Receivable | - | - | - | - | - |
Inventory | - | - | - | - | - |
Other Current Assets | 80.0K | 9.0K | 1.4M | 25.0K | 52.0K |
Total Current Assets | 395.9M | 374.1M | 504.7M | 27.3M | 5.6M |
Non-Current Assets | |||||
Property, Plant & Equipment | 3.0M | 4.3M | 2.4M | 1.2M | 1.6M |
Goodwill | - | 0 | 213.0K | 428.0K | 642.0K |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | - | - | - | - |
Total Non-Current Assets | 45.2M | 46.4M | 13.3M | 13.0M | 11.1M |
Total Assets | 441.1M | 420.6M | 518.0M | 40.3M | 16.7M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 3.6M | 5.1M | 3.0M | 2.8M | 781.0K |
Short-term Debt | 765.0K | 803.0K | 493.0K | 267.0K | 225.0K |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 36.2M | 25.0M | 10.9M | 12.3M | 5.5M |
Non-Current Liabilities | |||||
Long-term Debt | 2.5M | 3.6M | 1.9M | 1.1M | 1.3M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 3.2M | 4.2M | 2.2M | 1.1M | 1.3M |
Total Liabilities | 39.4M | 29.2M | 13.1M | 13.4M | 6.8M |
Equity | |||||
Common Stock | 29.0K | 23.0K | 24.0K | 188.4M | 116.2M |
Retained Earnings | -1.2B | -1.1B | -1.1B | -161.5M | -106.4M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 401.6M | 391.3M | 504.9M | 26.9M | 9.9M |
Key Metrics | |||||
Total Debt | 3.2M | 4.4M | 2.4M | 1.3M | 1.6M |
Working Capital | 359.7M | 349.1M | 493.8M | 15.0M | 83.0K |
Balance Sheet Composition
ProKidney Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -163.3M | -135.4M | -148.1M | -55.1M | -26.7M |
Depreciation & Amortization | 5.4M | 3.9M | 3.0M | 2.0M | 964.0K |
Stock-Based Compensation | 29.4M | 30.8M | 74.5M | 699.0K | 730.0K |
Working Capital Changes | 10.5M | 10.3M | 494.0K | 2.2M | -126.0K |
Operating Cash Flow | -118.2M | -90.5M | -70.1M | -50.3M | -25.2M |
Investing Activities | |||||
Capital Expenditures | -29.5M | -34.2M | -1.8M | -5.2M | -5.5M |
Acquisitions | - | - | - | - | - |
Investment Purchases | -324.0M | -471.6M | 0 | 0 | - |
Investment Sales | 373.9M | 175.8M | 0 | 0 | - |
Investing Cash Flow | 20.4M | -330.0M | -1.7M | -5.2M | -5.5M |
Financing Activities | |||||
Share Repurchases | 0 | -9.5M | 0 | 0 | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | -54.0K | -52.0K | -35.0M | -30.0K | -11.0K |
Financing Cash Flow | 144.3M | -9.6M | 513.5M | 71.5M | 20.0M |
Free Cash Flow | -155.9M | -124.3M | -78.9M | -55.5M | -30.6M |
Net Change in Cash | 46.5M | -430.0M | 441.6M | 16.0M | -10.6M |
Cash Flow Trend
ProKidney Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-3.69
Forward P/E
-4.65
Price to Book
0.88
Price to Sales
3,206.54
PEG Ratio
0.20
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-17,967.87%
Return on Equity
-40.52%
Return on Assets
-25.30%
Financial Health
Current Ratio
11.48
Debt to Equity
1.30
Beta
1.81
Per Share Data
EPS (TTM)
$-0.56
Book Value per Share
$-7.51
Revenue per Share
$0.00
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
prok | 1.7B | -3.69 | 0.88 | -40.52% | 0.00% | 1.30 |
Vertex | 100.7B | 27.94 | 5.86 | 22.77% | 31.86% | 8.89 |
Regeneron | 62.9B | 14.95 | 2.06 | 15.34% | 31.37% | 9.04 |
Adaptive | 2.0B | -12.07 | 11.04 | -57.60% | -59.07% | 121.39 |
Cg Oncology | 2.0B | -18.13 | 2.97 | -12.00% | 0.00% | 0.15 |
Vericel | 1.8B | 259.14 | 5.96 | 2.59% | 2.85% | 32.74 |
Financial data is updated regularly. All figures are in the company's reporting currency.